DOM-ZOLMITRIPTAN TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

ZOLMITRIPTAN

Mevcut itibaren:

DOMINION PHARMACAL

ATC kodu:

N02CC03

INN (International Adı):

ZOLMITRIPTAN

Doz:

2.5MG

Farmasötik formu:

TABLET

Kompozisyon:

ZOLMITRIPTAN 2.5MG

Uygulama yolu:

ORAL

Paketteki üniteler:

6/30

Reçete türü:

Prescription

Terapötik alanı:

SELECTIVE SEROTONIN AGONISTS

Ürün özeti:

Active ingredient group (AIG) number: 0134381001; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2012-07-23

Ürün özellikleri

PRODUCT MONOGRAPH
PR
DOM-ZOLMITRIPTAN
(ZOLMITRIPTAN FILM-COATED TABLETS)
2.5 MG
PR
DOM-ZOLMITRIPTAN ODT
(ZOLMITRIPTAN ORALLY DISPERSIBLE TABLETS)
2.5 MG
5-HT1 RECEPTOR AGONIST
MIGRAINE THERAPY
DOMINION PHARMACAL
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
DATE OF REVISION:
March 21, 2016
SUBMISSION CONTROL NO: 192863
_ _
_Dom-ZOLMITRIPTAN and Dom-ZOLMITRIPTAN ODT Product Monograph _
_Page 2 of 41 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................18
DOSAGE AND ADMINISTRATION
..............................................................................19
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................24
PART II: SCIENTIFIC INFORMATION
...............................................................................25
PHARMACEUTICAL INFORMATION
..........................................................................25
CLINICAL TRIALS
.......................................................................